Contact
searchSearch
HMP Global
Login

Biosimilars Topic Center

Featured

Stephen Speicher, MD
Videos
Technology for Biosimilar Substitution to Enhance Practice Efficiency and Financial Health
03/01/2024

Featuring Stephen V. Speicher, MD, MS

Featuring Stephen V. Speicher, MD, MS...
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS,...
03/01/2024
Journal of Clinical Pathways
Andre Harvin, PharmD, MS, MBA
Videos
The Impact of Biosimilars on the Business of Oncology
03/28/2023
Andre Harvin, PharmD, MS, MBA, discusses controlling costs in the business of oncology through biosimilar use.
Andre Harvin, PharmD, MS, MBA, discusses controlling costs in the business of oncology through biosimilar use.
Andre Harvin, PharmD, MS, MBA,...
03/28/2023
Journal of Clinical Pathways
James Gelfand, JD
Videos
Analyzing Pharmacy Benefits in Value-Based Oncology Pathways
10/14/2022
James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways...
James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways...
James Gelfand, JD, The ERISA...
10/14/2022
Journal of Clinical Pathways
Conference Coverage
Therapeutic Interchange Reduces Cost While Maintaining Quality of Care in the US Oncology Care Model
10/01/2022
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care...
10/01/2022
Journal of Clinical Pathways
Research Reports
Improving Biosimilar Adoption Rates and Affordability With Oncology Pathways
08/15/2022
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues...
08/15/2022
Journal of Clinical Pathways
Puneeth Indurlal, MD, MS
Videos
Analyzing the Financial Impact of Biosimilar Use in the Oncology Care Model for the US Oncology Network
07/12/2022
Puneeth Indurlal, MD, MS, describes his study on the utilization and financial impact of abiraterone therapeutic interchange in The Network during an Oncology Care Model performance period, a value-based care program from Medicare that...
Puneeth Indurlal, MD, MS, describes his study on the utilization and financial impact of abiraterone therapeutic interchange in The Network during an Oncology Care Model performance period, a value-based care program from Medicare that...
Puneeth Indurlal, MD, MS,...
07/12/2022
Journal of Clinical Pathways
Conference Coverage
Standardizing Utilization of Biosimilars in Oncology
07/06/2022
Findings from a recent real-world study suggest that use of an integrated electronic health record to standardize biosimilar utilization in oncology may reduce costs, without compromising quality and safety in care. 
Findings from a recent real-world study suggest that use of an integrated electronic health record to standardize biosimilar utilization in oncology may reduce costs, without compromising quality and safety in care. 
Findings from a recent...
07/06/2022
Journal of Clinical Pathways
Conference Coverage
Impact of Biosimilar Substitution on Provider Risk in Value-Based Oncology Payment Models
06/14/2022
Researchers at the 2022 ASCO Annual Meeting estimated the impact of biosimilar substitution on financial risk to providers in oncology value-based payments by applying simulation approaches to model the episode framing, pricing, and risk...
Researchers at the 2022 ASCO Annual Meeting estimated the impact of biosimilar substitution on financial risk to providers in oncology value-based payments by applying simulation approaches to model the episode framing, pricing, and risk...
Researchers at the 2022 ASCO...
06/14/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Primary Prophylaxis With G-CSF Biosimilars in Patients at Risk of Febrile Neutropenia
06/12/2022
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to...
06/12/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy
06/09/2022
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark...
06/09/2022
Journal of Clinical Pathways
News
Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study
06/09/2022
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US...
06/09/2022
Journal of Clinical Pathways

Expert Insights

Gary Lyman, MD
Interview
Do Oncology Biosimilars Have a Place in Clinical Pathways?
08/30/2018
Gary Lyman, MD, MPH, explains the process of bringing oncology biosimilars to market and their potential uptake in clinical practice as well as pathways.
Gary Lyman, MD, MPH, explains the process of bringing oncology biosimilars to market and their potential uptake in clinical practice as well as pathways.
Gary Lyman, MD, MPH, explains...
08/30/2018
Journal of Clinical Pathways
Interview
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
10/30/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
10/30/2024
Journal of Clinical Pathways
JB
Interview
The Road Ahead for CLL Research and Treatment: Overcoming Challenges and Embracing Innovations in Patient Care
10/25/2024
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements...
10/25/2024
Journal of Clinical Pathways
Jessica Paulus, ScD
Interview
Insights on Lung Cancer Diagnosis Trends and Screening Challenges in Community Oncology
10/23/2024
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica...
10/23/2024
Journal of Clinical Pathways
Edward R. (Ted) Arrowsmith
Interview
Optimizing NSCLC Clinical Pathways
10/10/2024
Join us as a guest expert discusses the evolving role of clinical pathways in guiding treatment decisions for non-small cell lung cancer in the era of precision medicine and targeted therapies, emphasizing the importance of patient-focused...
Join us as a guest expert discusses the evolving role of clinical pathways in guiding treatment decisions for non-small cell lung cancer in the era of precision medicine and targeted therapies, emphasizing the importance of patient-focused...
Join us as a guest expert...
10/10/2024
Journal of Clinical Pathways
Puneeth Indurlal
Interview
Support Made Smarter: Assessing the Unique Needs of Patients With Cancer
08/20/2024
Learn about the health-related social needs of patients with cancer, common types of distress reported by patients, and how assessment tools can inform the development of support services.
Learn about the health-related social needs of patients with cancer, common types of distress reported by patients, and how assessment tools can inform the development of support services.
Learn about the health-related...
08/20/2024
Journal of Clinical Pathways
Gunjan Sharma
Interview
Leveraging Data to Enhance Patient Care: Addressing Social Determinants of Health in Oncology Care
07/10/2024
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst...
07/10/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways
Paul Fu, MD
Interview
How Technology Can Improve Health Care Team Communication
06/17/2024
Paul Fu Jr, MD, MPH, City of Hope National Medical Center
Paul Fu Jr, MD, MPH, discusses the benefits of using technology to assist health team communication practices.
Paul Fu Jr, MD, MPH, discusses the benefits of using technology to assist health team communication practices.
Paul Fu Jr, MD, MPH, discusses...
06/17/2024
Journal of Clinical Pathways
Interview
Oncology Drug Shortages: Causes and Solutions
05/28/2024

 Ryan Motte, PharmD, CSP, Shields Health Solutions

 Ryan Motte, PharmD, CSP, Shields Hea...
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses...
05/28/2024
Journal of Clinical Pathways
Shaalan Beg, MD
Interview
CLL Treatment Updates and the Integration of AI into CLL Clinical Trials
05/20/2024
Shaalan Beg, MD, MBA, FASCO
Shaalan Beg, MD, MBA, FASCO, describes some of the recent advancements in the treatment of chronic lymphocytic leukemia (CLL).
Shaalan Beg, MD, MBA, FASCO, describes some of the recent advancements in the treatment of chronic lymphocytic leukemia (CLL).
Shaalan Beg, MD, MBA, FASCO,...
05/20/2024
Journal of Clinical Pathways

Newsfeed

News
Cost-Effectiveness of Primary Prophylaxis With G-CSF Biosimilars in Patients at Risk of Febrile Neutropenia
06/12/2022
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to...
06/12/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy
06/09/2022
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark...
06/09/2022
Journal of Clinical Pathways
News
Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study
06/09/2022
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US...
06/09/2022
Journal of Clinical Pathways
News
Outcomes of Treatment With Cancer Biosimilars Found Equal to Those of the Reference Drug in Harvard Systematic Review and Meta-Analysis
05/11/2022
Study findings show that results of rigorous clinical evaluation of cancer drug biosimilars were statistically indistinguishable when compared with the results of evaluations of the reference drug across subgroups of drugs, cancer types, and...
Study findings show that results of rigorous clinical evaluation of cancer drug biosimilars were statistically indistinguishable when compared with the results of evaluations of the reference drug across subgroups of drugs, cancer types, and...
Study findings show that results...
05/11/2022
Journal of Clinical Pathways
News
Biosimilar vs Referent Trastuzumab for the Neoadjuvant Treatment of ERBB2–Positive Breast Cancer
04/14/2022
Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.
Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.
Biosimilar HD201 demonstrates...
04/14/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilars Safe, Effective Among Patients With HER2-Positive Breast Cancer
03/07/2022
Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.
Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.
Study findings show that...
03/07/2022
Journal of Clinical Pathways
News
Biosimilars Provide Lower-Cost Alternatives to Biologics Used in Cancer Care
02/25/2022
Findings from a recent update on currently approved oncology biosimilars suggests that the use of biosimilars might provide competitive, lower-cost alternatives to biologics used in oncology.
Findings from a recent update on currently approved oncology biosimilars suggests that the use of biosimilars might provide competitive, lower-cost alternatives to biologics used in oncology.
Findings from a recent update on...
02/25/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Primary Prophylaxis With Biosimilar Filgrastim for Patients at Risk for Febrile Neutropenia
02/21/2022
Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.
Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.
Study findings reveal primary...
02/21/2022
Journal of Clinical Pathways
News
Conversion to Biosimilar Neutropenia Prophylaxis Generates Cost-Savings and Provides Access to Pancreatic Cancer Treatment
02/11/2022
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar...
02/11/2022
Journal of Clinical Pathways
News
Biosimilar Trastuzumab is Cost-Efficient Over Reference Trastuzumab for Metastatic Breast Cancer
02/10/2022
Study findings suggest biosimilar intravenous trastuzumab-dkst is cost-efficient over reference intravenous and subcutaneous trastuzumab in metastatic breast cancer.
Study findings suggest biosimilar intravenous trastuzumab-dkst is cost-efficient over reference intravenous and subcutaneous trastuzumab in metastatic breast cancer.
Study findings suggest...
02/10/2022
Journal of Clinical Pathways
News
Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
Under 50% of Oncology Practices Offer Survivorship Clinics
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
News
Advancing Personalized Treatment in Endometrial Cancer With the HECTOR Deep Learning Model
11/06/2024
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
News
Influence of Socioeconomic and Demographic Factors on Myelofibrosis Outcomes
10/30/2024
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic...
10/30/2024
Journal of Clinical Pathways
News
Hypertension and Endometrial Cancer Risk: A Systematic Review and Meta-Analysis
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways
News
Harnessing the Potential of Abemaciclib in Recurrent Endometrial Cancer Treatment
10/25/2024
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor...
10/25/2024
Journal of Clinical Pathways
News
Pembrolizumab Plus Adjuvant Chemotherapy for Newly Diagnosed High-Risk dMMR Endometrial Cancer
10/21/2024
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with...
10/21/2024
Journal of Clinical Pathways
News
False Negatives More Prevalent in Endometrial Cancer Screening for Black Women
10/17/2024
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA...
10/17/2024
Journal of Clinical Pathways
News
Efficacy of Momelotinib in Managing Anemia in Myelofibrosis: Results from the SIMPLIFY-2 Trial
10/16/2024
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in...
10/16/2024
Journal of Clinical Pathways

From the Journal

Research Reports
Improving Biosimilar Adoption Rates and Affordability With Oncology Pathways
08/15/2022
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues...
08/15/2022
Journal of Clinical Pathways
Research Reports
Implications of Manufacturer Contracting: A Quantitative Model to Assess Biosimilar Market Feasibility
10/15/2018
Abstract: Eight years have passed since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Since then, 12 biosimilars have received approval from the Food and Drug Administration,...
Abstract: Eight years have passed since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Since then, 12 biosimilars have received approval from the Food and Drug Administration,...
...
10/15/2018
Journal of Clinical Pathways
Research Reports
Community Oncologists` Perception and Acceptance of Biosimilars in Oncology
09/13/2018
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
...
09/13/2018
Journal of Clinical Pathways
Perspectives
Facing Cancer as a Chronic Disease: Shared Decision-Making at Critical Points in a Long Illness Journey
10/01/2024
In this third installment of a three-part series on decision support tools and shared decision-making, Christine Wilson, MA, MS, and colleagues describe how patients with­in three diverse communities who are living with cancer understand and...
In this third installment of a three-part series on decision support tools and shared decision-making, Christine Wilson, MA, MS, and colleagues describe how patients with­in three diverse communities who are living with cancer understand and...
In this third installment of a...
10/01/2024
Journal of Clinical Pathways
Perspectives
Who Uses Pathways Around Care Management?
10/01/2024
This pilot study provides a brief literature review on users, uses, and a recent electronic survey to de­termine how users use clinical pathways along with their feedback around their value.
This pilot study provides a brief literature review on users, uses, and a recent electronic survey to de­termine how users use clinical pathways along with their feedback around their value.
This pilot study provides a...
10/01/2024
Journal of Clinical Pathways
Research Reports
Time to Treatment and the “Golden Hour”: Why They Matter and How Clinical Pathways Can Help
08/19/2024
This study explores how clinical pathways can help reduce time to treatment delays while improving health care quality, lowering direct and indirect health care costs, reducing patient financial toxicity, and achieving greater patient,...
This study explores how clinical pathways can help reduce time to treatment delays while improving health care quality, lowering direct and indirect health care costs, reducing patient financial toxicity, and achieving greater patient,...
This study explores how clinical...
08/19/2024
Journal of Clinical Pathways
From the Field
Bridging the Gap Between Oncologists and Payers: Impact of an EHR-Embedded CDS Tool in Oncology Clinical Pathway (OCP) Adherence
08/15/2024
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers...
08/15/2024
Journal of Clinical Pathways
Perspectives
Individualized Care Through Treatment Pathways: Isn’t This an Oxymoron?
06/26/2024
This article describes how congruent solutions for treatment options can be achieved if the objectives of precision medicine and treatment pathways are aligned.
This article describes how congruent solutions for treatment options can be achieved if the objectives of precision medicine and treatment pathways are aligned.
This article describes how...
06/26/2024
Journal of Clinical Pathways
From the Field
Shifting the Paradigm: The Impact of AI at the Point of Care in Cancer Treatment
06/03/2024
This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.
This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.
This report explores the...
06/03/2024
Journal of Clinical Pathways
Research Reports
PSA Outcomes and Clinical Surveillance Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With a Next-Generation Androgen Receptor Inhibitor in Urology Practices With or Without In-Office Dispensing
06/03/2024
Sabree C. Burbage, PharmD
Dexter Waters, MSPH
Carmine Rossi, PhD
Frederic Kinkead, MA
Erik Muser, PharmD
Lorie Ellis, PhD
Patrick Lefebvre, MA
Dominic Pilon, MA
This study describes prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs)...
This study describes prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs)...
This study describes...
06/03/2024
Journal of Clinical Pathways
From the Field
Bringing Value to Health Care
06/03/2024
This paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.
This paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.
This paper provides insights and...
06/03/2024
Journal of Clinical Pathways
Research Reports
Patient-Reported Outcomes in Hematopoietic Stem Cell Transplant Recipients: Design, Implementation, and Pilot Results
02/21/2024
In a recent study, Christi Ann Hayes, MD, and colleagues aimed to define patient-reported outcome measures in patients receiving hematopoietic stem cell transplant.
In a recent study, Christi Ann Hayes, MD, and colleagues aimed to define patient-reported outcome measures in patients receiving hematopoietic stem cell transplant.
In a recent study, Christi Ann...
02/21/2024
Journal of Clinical Pathways
From the Field
Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
02/12/2024
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al...
02/12/2024
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

Stephen Speicher, MD
Videos
Technology for Biosimilar Substitution to Enhance Practice Efficiency and Financial Health
03/01/2024

Featuring Stephen V. Speicher, MD, MS

Featuring Stephen V. Speicher, MD, MS...
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS, discusses his upcoming AMCCBS poster presentation titled “Technology for Substituting Biosimilars to Improve Practice Efficiency and Financial Health.”
Stephen V. Speicher, MD, MS,...
03/01/2024
Journal of Clinical Pathways
Andre Harvin, PharmD, MS, MBA
Videos
The Impact of Biosimilars on the Business of Oncology
03/28/2023
Andre Harvin, PharmD, MS, MBA, discusses controlling costs in the business of oncology through biosimilar use.
Andre Harvin, PharmD, MS, MBA, discusses controlling costs in the business of oncology through biosimilar use.
Andre Harvin, PharmD, MS, MBA,...
03/28/2023
Journal of Clinical Pathways
James Gelfand, JD
Videos
Analyzing Pharmacy Benefits in Value-Based Oncology Pathways
10/14/2022
James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways...
James Gelfand, JD, The ERISA Industry Committee, discusses achieving optimal, value-driven patient care through pharmacy benefit managers, and changes in plan transparency for payers and patients at the 2022 Oncology Clinical Pathways...
James Gelfand, JD, The ERISA...
10/14/2022
Journal of Clinical Pathways
Conference Coverage
Therapeutic Interchange Reduces Cost While Maintaining Quality of Care in the US Oncology Care Model
10/01/2022
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care...
10/01/2022
Journal of Clinical Pathways
Research Reports
Improving Biosimilar Adoption Rates and Affordability With Oncology Pathways
08/15/2022
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.
Dr Hamilton and colleagues...
08/15/2022
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use